You, your Career and BioTech

Sometimes it is easy to forget that your job and your career are two different things. Your job is what you do for your employer. Your career is the path that will get your through a sequence of jobs to achieve your personal goals. Your career will be influenced by events outside of your control, like life events or the economy, but you do have some control over your career and you should use it.

A few weeks ago I gave a presentation on this topic to the CS Seniors at CSUM – Cal State University Monterrey Bay – as part of a series on Life After College. The short summary of the presentation was:

  • Your Job is not your Career – You are in charge of your Career,
  • Software is a key part of BioTech,
  • You should consider adding BioTech to your career Choices.

During the presentation I used as an example Freenome, an early stage BioTech company that I joined at the end of 2020 after spending most of my career in HiTech.

I re-recorded the presentation into a 9 minute video that you can see HERE.

Enjoy and stay connected!

And Freenome is Hiring!

Change is Good – 11 years after Sun Microsystems

Change is Good!

The acquisition of Sun Microsystems by Oracle Corp closed 11 years ago, on Jan 27th, 2010, 9 months after it was first announced.

I had been at Sun for many years and I really liked what I was doing but, in hindsight, the acquisition forced me to accept change, and that was good.  I stayed at Oracle for a few months, and then left for BlackBerry (then RIM) where I joined other ex-Sun people, learned new things and shared some of what I had learned with new colleagues in a different community. 

I believe that embracing change, and exchanging communities, is a key asset in our industry.  We learn new things through experimentation and observation, and then reshuffle and try again in a new environment.  And, collectively, we move forward.

I reported on the beginning of the Sun exodus a year after the acquisition: people and OSS projects. The process has continued, though I have only tracked the movement through my direct friends.  On a personal level, after BlackBerry I joined Progress, and then CloudBees.

I’m now at Freenome.   I joined for three main reasons:

  • Cancer sucks and I believe I can help Freenome in its mission.
  • I can learn new things: Biology, ML, Workflows, Python, Continuous Improvement in a Regulated Industry, and many other topics
  • The company culture is outstanding

The change to Freenome is arguably the biggest change so far for me, from hiTech to bioTech. This change enables many opportunities for learning and teaching across these two industries, and I will write about that in the future but, in the meantime…

Change may sometimes be scary but, change is good!  My lesson is to embrace it and keep growing…   

And ping me if you are considering a move to BioTech.  Particularly if Freenome has any appeal to you.

Freenome Bloggers

A list of Freenome people writing about Freenome events and content.

Freenome/Blog

A collection of links to blog posts from Freenome people about Freenome…

Teddy

Eduardo

CRC and Freenome

A collection of links to and extracts from public information on CRC and Freenome (last updated on Feb 14, 2021). Also see similar post collections on Social Topics, and Technology/Science.

Disclaimer: I am a Software guy, barely beginning to learn the Biology side of all this :). Plus this post is WiP

From Wikipedia: “Colorectal cancer (CRC) is the development of cancer from the colon or rectum“. Also see American Cancer Society and Mayo Clinic. Wikipedia maintains a List of (Public) People Diagnosed with CRC; a notable recent death was that of Chadwick Boseman.

Unless indicated otherwise, the links below are to Freenome Press Releases with an excerpt and an occasional brief commentary.

(Oct ‘18) Freenome Unveils Promising Early Data on Colorectal Cancer Screening Test at American College of Gastroenterology Annual Meeting

The current lack of an effective, blood-based test may be a contributing factor to low rates of CRC screening today, with nearly 1 in 3 adults aged 50-75 years non-adherent with screening guidelines. Existing methods, such as colonoscopy and stool-based testing, are often seen as inconvenient and uncomfortable by patients, leading many to postpone or forgo recommended screenings

A concise description of the value of a blood-based screening for CRC.

and

We have shown that it’s possible to take a machine learning–based approach to decode the relationship between a patient’s cell-free DNA profile and his or her cancer status, detecting CRC in our dataset with a top performance of 82% sensitivity at 85% specificity. These are very encouraging data that support the continued development of a CRC screening test that includes cfDNA and machine learning as key components.

Above is a quote from Freenome’s Chief Medical Officer, Girish Putcha. Sensitivity is a measure of how well the test can identify true positives, while Specifity is a measure of how well the test can identify true negatives (see Wikipedia). There is a trade-off between sensitivity and specificity and, as indicated in public reports elsewhere one of the key benefits of the Freenome approach is that we can tune the tradeoff depending on the cancer and the treatments.

(Jan ‘20) Freenome Announces Encouraging Performance Data for Its Multiomics Blood Test to Detect Early-Stage Colorectal Cancer in a Prospective, Multi-Center Clinical Study

Freenome’s multiomics blood test can detect early-stage colorectal cancer (stage I/II) at 94% sensitivity and 94% specificity.

The improved sensitivity and specificity above numbers reflect advances since the earlier results reported in Oct 2018. The test reported here combines cell-free DNA (cfDNA) as well as protein biomarkers into a machine-learning classifier.

(May ‘20) Freenome Announces Initiation of the PREEMPT CRC Clinical Trial, a Registrational Study for the Early Detection and Prevention of Colorectal Cancer Using a Multiomics Blood Test 

Following strong data presented at ASCO-GI … we are initiating the pivotal trial for our blood-based CRC test

Initiation of the CRC Clinical Trial

PREEMPT CRC is Freenome’s prospective clinical trial that will enroll 14,000 individuals to validate its multiomics blood test for CRC screening and FDA approval. The study will include asymptomatic, average-risk patients between the ages of 45 and 85 undergoing a screening colonoscopy.

And some details of the CRC Clinical Trial.

(Jan ‘21) Freenome’s Multiomics Blood Test Shows Promising Results in Detecting Colorectal Advanced Adenomas  

multiomics blood test can detect colorectal advanced adenomas at 41% sensitivity and 90% specificity,

Concise description of the result.

The data from a pre-defined subset of AI-EMERGE® (n=522) showed that Freenome’s novel multiomics blood test for colorectal cancer screening was able to detect colorectal advanced adenomas (AAs) with a sensitivity of 41% at a specificity of 90%. Compared with the FDA-approved mSEPT9 (methylated septin 9) blood test, Freenome’s multiomics blood test showed much higher sensitivity (41% vs. 22%)1 for detecting AAs. When compared to currently available stool-based tests, the test demonstrated much higher AA sensitivity than a fecal immunochemical test, or FIT (41% vs. 24%) and comparable AA sensitivity to FIT-DNA (41% vs. 42%)2

And more details. Note that, unlike the report from 2020, this one is reporting on Advanced Adenomas, i.e. pre-cancer.

Freenome is Hiring!

Freenome is hiring!

The mission can’t be better…

The technology stack is mostly Python in the back-end, on K8s and GCP (et al.), and React in the front-end. I’ll provide more insight as I ramp up in 2021 but you can look at the openings in the Freenome career’s page. There are two relevant groups of openings, one for Computational Science and one for Engineering – I am in the Engineering group, and I’d expect most of my friends/contacts to be in that area but look around. The core approach is multiomics, using molecular biology and machine learning to detect cancers in blood, so regardless of where you land, Freenome would give you an opportunity to learn about those two areas.

The company’s HQ is in South San Francisco, in the Verily campus which includes the usual Alphabet goodies. We are all working from home right now, and there is some remote work flexibility.

… and now at Freenome!

Today (Dec 28th), I started at Freenome. Freenome is developing and productizing a Multiomics platform for early cancer detection. The tag line is “Spot the pattern, treat the cancer“. Multiomics means doing analysis on data from multiple “omes“, i.e. using fragments of DNA, RNA, proteins and other biomarkers from blood plasma. The first study is PREEMPT CRC – Colorectal Cancer.

I am joining as an Engineering Manager, same role as what I had at CloudBees. The technology platform is mostly Python in the back-end, plus JS in the front-end, plus… I’ll find out.

I’m very excited to join Freenome. I liked the team and the company, and loved the mission! I’ve lost multiple friends and relatives to Cancer, and I myself had an early encounter with Prostate Cancer, so any little thing I can do to help, sign me in!

Freenome is located in South San Francisco, close to many other BioTech companies, and has a strong list of partners and investors. In the short-term, I will be working from home – like everybody else.

Some of my reading material 🙂